Lung Cancer in China
Overview
Lung cancer arises in the airways or lung tissue, with non-small cell lung cancer (NSCLC) accounting for about 85% of cases. Over the past decade outcomes have been transformed by low-dose CT screening, minimally invasive surgery and targeted and immune therapies matched to each tumor’s biology.
China diagnoses and treats the world’s largest lung cancer population; its national cancer centers offer genomic profiling, robotic resection and domestically developed targeted drugs, several of which reached clinical use years ahead of some international markets.
Symptoms & Signs
Persistent cough, or a change in the character of a long-standing smoker’s cough
Coughing up blood, chest pain and breathlessness
Recurrent pneumonia or bronchitis in the same lung region
Unexplained weight loss, fatigue and loss of appetite
Hoarseness from recurrent laryngeal nerve involvement, or facial swelling from vessel compression
Early-stage tumors often cause no symptoms and are found on low-dose CT screening
Diagnosis
Low-dose CT for screening and pulmonary nodule detection in high-risk individuals
PET-CT for whole-body staging of proven cancers
Bronchoscopy with biopsy, navigational bronchoscopy or CT-guided needle biopsy for tissue
EBUS-TBNA minimally invasive staging of mediastinal lymph nodes
Next-generation sequencing (NGS) profiling EGFR, ALK, ROS1, KRAS and PD-L1 to guide therapy
Molecular liquid biopsy for genotyping and treatment monitoring
Treatment Options
Minimally invasive (VATS or robotic) lobectomy with lymph node dissection for operable early disease
Sublobar (segmentectomy) resection for small screen-detected nodules, preserving lung function
SBRT stereotactic body radiotherapy delivering curative doses for patients unfit for surgery
Targeted therapy (EGFR, ALK, ROS1 inhibitors) for driver-mutation cancers, often as first-line treatment
Immunotherapy (PD-1/PD-L1 inhibitors) alone or with chemotherapy for mutation-negative disease
Multidisciplinary combined-modality care for stage III disease and oligometastatic cases
Advanced Technologies & Novel Drug
da Vinci robotic and single-port VATS lung resection
Navigational and robotic bronchoscopy reaching peripheral nodules for early diagnosis
Next-generation sequencing platforms with rapid turnaround
Domestically developed EGFR inhibitors (e.g. aumolertinib-class) and anti-PD-1 agents approved first in China
Novel antibody-drug conjugates for refractory disease available through major cancer centers
Hospital & Specialist
- Cancer Hospital, Chinese Academy of Medical Sciences (CICAMS) — Beijing
- Sun Yat-sen University Cancer Center (SYSUCC) — Guangzhou
- Shanghai Chest Hospital (Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University School of Medicine) — Shanghai
- Fudan University Shanghai Cancer Center (FUSCC) — Shanghai
- Qiu Wei Cheng — Thoracic Surgery
- Jiang Ge Ning — Thoracic Surgery
- Li Jun Ling — Medical Oncology
- Wang Xing Yuan — Medical Oncology